Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Holding SRPT?
Track your performance easily
SRPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.25 - $173.25
Previous Close$124.53
Volume768.36K
Average Volume (3M)1.05M
Market Cap
$11.88B
Enterprise Value$11.79B
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)307.9
Beta0.65
Next Earnings
Oct 30, 2024EPS Estimate
$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding95,366,334
10 Day Avg. Volume689,768
30 Day Avg. Volume1,046,887
Standard Deviation0.15
R-Squared0.08
Alpha0.00929
Financial Highlights & Ratios
Price to Book (P/B)11.03
Price to Sales (P/S)7.89
Price to Cash Flow (P/CF)198.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.83
Enterprise Value/Gross Profit10.78
Enterprise Value/Ebitda68.38
Forecast
1Y Price Target
$195.20Price Target Upside56.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Sarepta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceAnalysts are encouraged by the 2025 guidance, especially as it should remove prior concerns surrounding near-term manufacturing constraints.
Market OpportunityMarket reaction due to the Elevidys miss is overdone, representing a great entry opportunity.
Revenue GrowthSarepta is uniquely positioned to leverage its expertise, access, and leadership to drive Elevidys revenue growth.
Bears Say
Market SentimentAmbiguity in the Elevidys sales forecast/launch curve could serve as an overhang for shares near-term.
Revenue GuidanceThe wisdom of offering such a tight range 16 months out, when estimates already seem achievable, has drawn significant investor concern.
Sales PerformanceElevidys sales for the second quarter were below consensus estimates, with management also providing comments on the 2024 launch curve and 2025 revenue guidance that may disappoint investors.
---
Ownership Overview
449.42% Insiders
2741.07% Mutual Funds
3049.80% Other Institutional Investors
1699.49% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $55.25 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Currently, no data Available
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Oct 30, 2024 which is 13 days ago.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 07, 2024. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of -$0.129 by $0.199.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is $0.04.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 95,366,330 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.07 in its last earnings report, beating expectations of -$0.129. Following the earnings report the stock price went down -2.613%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Among the largest hedge funds holding Sarepta Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Sarepta Therapeutics’s shares valued at 363M.
---
Sarepta Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$195.20 (56.75% Upside)
$195.20 (56.75% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 696.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.88%
12-Months-Change
Fundamentals
Return on Equity
5.20%
Trailing 12-Months
Asset Growth
9.54%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
---
SRPT Earnings Call
Q2 2024
0:00 / 0:00
---
SRPT Stock 12 Month Forecast
Average Price Target
$195.20
▲(56.75% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Vertex Pharmaceuticals
―
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
14/19 ratings generated profit
1 Year Average Return
+17.16%
reiterated a buy rating 4 months ago
Copying Uy Ear's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +17.16% per trade.
---